Johnson & Johnson (JNJ) holds a leadership position across multiple healthcare segments, including pharmaceuticals, medical devices, and over-the-counter consumer products. This helps JNJ consistently create impressive free cash flow, which has allowed the company to grow its dividend for over 50 years in a row. Of course, these qualities don't come cheap. Recently, the stock has fallen 10% off of all-time highs, and I believe this makes the stock reasonably valued and within buy territory. My opinion is based on multiple valuation approaches, including historical multiples, comparables, and a discounted cash flow analysis.
JNJ's Financial Snapshot
JNJ's performance continues to impress, which includes 6% revenue growth during 2017. Net income and EPS in the table below include a large expense from recent tax legislation. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for 2017 was $20.0 billion, and adjusted EPS was $7.30, representing increases of 6.8% and 8.5%, respectively. JNJ's net cash position dropped considerably in 2017 because of the $30 billion acquisition of Actelion. This isn't much of an issue for JNJ, given its strong free cash flow production, so cash stockpiles should be able to be replenished.
READ FULL ARTICLE HERE

